Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Current status of treatment for primary effusion lymphoma.
[primary effusion lymphoma]
Primary
effusion
lymphoma
(
PEL
)
is
a
rare
and
aggressive
B-
cell
non-
Hodgkin
's
lymphoma
that
usually
presents
with
malignant
effusions
without
tumor
masses
.
An
extracavitary
or
solid
variant
of
PEL
has
also
been
described
.
Human
herpes
virus
8
/
Kaposi
sarcoma
-associated
herpes
virus
(
HHV-
8
/
KSHV
)
is
universally
associated
with
the
pathogenesis
of
PEL
.
More
than
70
%
of
cases
occur
with
concurrent
Epstein-
Barr
virus
infection
,
but
its
relation
to
the
pathogenesis
is
unknown
.
Patients
are
found
in
the
context
of
immunosuppressive
states
(
HIV-
1
infection
,
post-organ
transplantation
)
.
PEL
is
usually
treated
with
CHOP
(
cyclophosphamide
,
doxorubicin
,
vincristine
,
and
prednisone
)
-
like
chemotherapy
with
antiretroviral
therapy
if
HIV-
1
is
positive
.
However
,
it
is
generally
resistant
to
chemotherapy
with
a
short
median
survival
of
less
than
6
months
.
The
optimal
treatment
for
PEL
has
not
been
established
yet
.
More
intensive
chemotherapy
,
such
as
dose-adjusted
EPOCH
(
DA-EPOCH
;
etoposide
,
prednisone
,
vincristine
,
cyclophosphamide
and
doxorubicin
)
and
CDE
(
cyclophosphamide
,
doxorubicin
,
etoposide
)
are
expected
to
show
a
favorable
prognosis
.
Recently
,
the
molecular
steps
in
KSHV
/
HHV-
8
-
driven
oncogenesis
have
begun
to
be
revealed
,
and
molecular
targeting
therapies
such
as
proteasome
,
NF-κB
,
cytokines
and
surface
antigens
would
provide
evidence
for
their
clinical
use
.
Diseases
Validation
Diseases presenting
"sarcoma-associated"
symptom
hodgkin lymphoma, classical
primary effusion lymphoma
waldenström macroglobulinemia
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom